newsfilter
← Latest News
GlobeNewswire·

Cingulate Receives Complete Response Letter from FDA for CTx-1301

No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related RequestsCompany Plans Prompt Response and Submission of Requested InformationCompany is Well Capitalized with